Retrophin, LLC Initiates Global Access For RE-024 In Pantothenate Kinase-Associated Neurodegeneration (PKAN)
Published: May 12, 2014
NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced that it has made RE-024 available to physicians who are treating critically ill patients with pantothenate kinase-associated neurodegeneration (PKAN) worldwide under local “compassionate use” regulations. RE-024 is a replacement therapy for phosphopantothenate, the reaction product and substrate that is missing in patients with PKAN.
Help employers find you! Check out all the jobs and post your resume.